SCHEMBL2448451

SCHEMBL2448451

COCc1ccc(-c2cc(C(C)(C)C)c(OC)c3cc(N4CCC(CNS(C)(=O)=O)C4)cnc23)c(OC)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK1 P51617 1/20 0.36
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
ALOX15 P16050 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
GAA P10253 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SMO Q99835 1/20 0.33
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
RAF1 P04049 1/20 0.32
LYN P07948 1/20 0.32
BRAF P15056 1/20 0.32
EPHA2 P29317 1/20 0.32
EPHA3 P29320 1/20 0.32
AKT1 P31749 1/20 0.32
MAPK9 P45984 1/20 0.32
PIK3CD O00329 3/20 0.32
PIK3R1 P27986 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2448450 1.00 IRAK1 (0.36) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL1703312 0.86 IRAK1 (0.34) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL2450995 0.85 IRAK1 (0.38) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL2450996 0.85 IRAK1 (0.38) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL1703017 0.83 IRAK1 (0.35) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL2448595 0.83 AURKA (0.36) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL2452207 0.83 IRAK1 (0.35) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL2448864 0.82 CYP3A4 (0.40) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL3796409 0.82 CYP3A4 (0.40) IRAK1KDM4EALDH1A1MAPTALOX15
SCHEMBL2452968 0.81 IRAK1 (0.34) IRAK1KDM4EALDH1A1MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440528-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-10-08 EP disclosed
US-8487103-B2 Quinoline inhibitors of hepatitis C virus polymerase ROCHE PALO ALTO LLC (US) 2013-07-16 US disclosed
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC (US) 2011-12-08 US disclosed
US-8026253-B2 Quinoline inhibitors of HCV polymerase ROCHE PALO ALTO LLC (US) 2011-09-27 US disclosed
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS DE VICENTE FIDALGO JAVIER 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311760-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, XDH, GTF3C4 IRAK1 2850/4885KDM4E 1276/4885ALDH1A1 1266/4885
US-20110300103-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, ZC3HAV1, IRF3 IRAK1 2103/4885KDM4E 1344/4885ALDH1A1 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.